Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
AssigneeAttillaps Holdings
InventorFrank Anthony Spallitta
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention involve treating ophthalmology conditions by the topical or oral use of acetylcholinesterase inhibitors. By effectively reducing or eliminating the population of Demodex mites in affected areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the ophthalmological afflictions than any previously described method. Embodiments of the invention are useful for treating ocular afflictions caused by Demodex-induced inflammatory eye conditions, including meibomian gland dysfunction, conjunctivitis, keratoconjunctivitis, hyperemia, blepharitis and dry eye disease.
Claims18
A method of treating an ophthalmological affliction, the method comprising the step of orally administering or topically applying to an individual having the ophthalmological affliction an acetylcholinesterase inhibitor in a dosage sufficient to inactivate Demodex brevis and/or Demodex folliculorum mites from hair follicles, skin, eyes, eyelids, eyelashes, or meibomian glands of the individual, resulting in amelioration or cessation of the manifestations of allergic and/or inflammatory responses to the mites that cause symptoms and signs of the ophthalmological affliction in the individual;
- wherein the individual is a human and the acetylcholinesterase inhibitor is selected from the group consisting of:
- physostigmine, demecarium, donepezil, tacrine, echothiophate, diisopropyl fluorophosphate, lactucopicrin, Boswellia, Celastrus paniculatus, coumarins, galantamine, huperzine A, and a prodrug or pharmaceutically acceptable salt thereof.
A method of treating an ophthalmological affliction, the method comprising a step of topically applying to an eye region of an individual having the ophthalmological affliction that is a Demodex-induced inflammatory eye condition an active ingredient comprising an acetylcholinesterase inhibitor in a dosage sufficient to inactivate Demodex brevis and/or Demodex folliculorum mites from said eye region, wherein said eye region comprises hair follicles, skin, eyes, eyelids, eyelashes, or meibomian glands of the individual, resulting in amelioration or cessation of one or more manifestations of allergic and/or inflammatory responses to the mites that cause symptoms and signs of the ophthalmological affliction in the individual, wherein the topically applied active ingredient is applied to the said hair follicles, skin, eyes, eyelids, eyelashes, or meibomian glands areas affected by the ophthalmological affliction and to areas not affected by the ophthalmological affliction;
- wherein the individual is a human and the acetylcholinesterase inhibitor is selected from the group consisting of:
- physostigmine, demecarium, donepezil, tacrine, echothiophate, diisopropyl fluorophosphate, lactucopicrin, Boswellia, Celastrus paniculatus, coumarins, galantamine, huperzine A, and a prodrug or pharmaceutically acceptable salt thereof.
A method of treating an individual having a Demodex induced inflammatory eye condition, the method comprising the steps of:
- applying to the individual in need thereof an acetylcholinesterase inhibitor in a dosage sufficient to inactivate Demodex brevis mites and/or Demodex folliculorum mites from an eye region of the individual, wherein the eye region includes one or more of hair follicles, eyelids, eyelashes and Meibomian glands in and around an eye region;
- wherein a sufficient amount of Demodex brevis mites and/or Demodex folliculorum mites are inactivated to ameliorate or cease manifestations of allergic and/or inflammatory responses to the Demodex mites that cause the inflammatory eye condition;
- wherein the individual is a human and the acetylcholinesterase inhibitor is selected from the group consisting of:
- physostigmine, demecarium, donepezil, tacrine, echothiophate, diisopropyl fluorophosphate, lactucopicrin, Boswellia, Celastrus paniculatus, coumarins, galantamine, and huperzine A, and a prodrug or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.